Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 2

Status

Unknown 2Completed 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 7Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 149Breast Neoplasms 87Colorectal Neoplasms 64Neoplasms 53Pancreatic Neoplasms 52Lung Neoplasms 49Neoplasm Metastasis 45Stomach Neoplasms 43Ovarian Neoplasms 42Rectal Neoplasms 41Esophageal Squamous Cell Carcinoma 34Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 30Head and Neck Neoplasms 30Leukemia, Myeloid, Acute 28Recurrence 23Triple Negative Breast Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Small Cell Lung Carcinoma 20Nasopharyngeal Carcinoma 20Glioblastoma 20Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Lymphoma, Non-Hodgkin 18Lymphoma 18Colonic Neoplasms 17Prostatic Neoplasms 16Leukemia 15Carcinoma, Ovarian Epithelial 15Melanoma 14

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Drug Therapy × Clear all
NCT06238752 2024-02-02

RENMIN-213

Renmin Hospital of Wuhan University

Phase 2 Completed
33 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT06121700 2023-11-08

Miracle-G

Fudan University

Phase 2 Recruiting
55 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT04384601 2021-07-19

Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer

Ruijin Hospital

Phase 3 Not yet recruiting
246 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
192 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00455936 2010-10-25

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

National Cancer Center, Korea

Phase 3 Completed
315 enrolled
Thoracic

Adenocarcinoma, Lung Neoplasms

NCT00358566 2008-05-19

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Pharmexa A/S

Phase 3 Terminated
360 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡